Literature DB >> 17689296

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Tania M Welzel1, Barry I Graubard, Hashem B El-Serag, Yasser H Shaib, Ann W Hsing, Jessica A Davila, Katherine A McGlynn.   

Abstract

BACKGROUND & AIMS: Intrahepatic and extrahepatic cholangiocarcinomas are rare and highly malignant cancers of the bile duct. Although the incidence of extrahepatic cholangiocarcinoma (ECC) has remained constant, the incidence of intrahepatic cholangiocarcinoma (ICC) has increased in the United States. Because the etiology of both tumors is poorly understood, a population-based case-control study was conducted to examine the association of ECC and ICC with preexisting medical conditions.
METHODS: Medical conditions among 535 ICC patients, 549 ECC patients (diagnosed 1993-1999), and 102,782 cancer-free controls were identified by using the Surveillance, Epidemiology and End Results-Medicare databases. Logistic regression analysis was used to calculate adjusted odds ratios.
RESULTS: In addition to established risk factors (choledochal cysts, cholangitis, inflammatory bowel disease), several other conditions were significantly associated with ECC and ICC: biliary cirrhosis (ECC, ICC: P < .001), cholelithiasis (ECC, ICC: P < .001), alcoholic liver disease (ECC, P < .001; ICC, P = .01), nonspecific cirrhosis (ECC, ICC: P < .001), diabetes (ECC, ICC: P < .001), thyrotoxicosis (ECC, P = .006; ICC, P = .04), and chronic pancreatitis (ECC, ICC: P < .001). Conditions only associated with ICC were obesity (ECC, P = .71; ICC, P = .01), chronic nonalcoholic liver disease (ECC, P = .08; ICC, P = .02), HCV infection (ECC, P = .67; ICC, P = .01), and smoking (ECC, P = .07; ICC, P = .04).
CONCLUSIONS: Several novel associations with ECC and ICC were identified. HCV infection, chronic nonalcoholic liver disease, and obesity, all of which are increasing in incidence, and smoking were associated only with ICC, suggesting that these conditions might explain the divergent incidence trends of the tumors.

Entities:  

Mesh:

Year:  2007        PMID: 17689296      PMCID: PMC2083573          DOI: 10.1016/j.cgh.2007.05.020

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  50 in total

1.  Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.

Authors:  F Donato; U Gelatti; A Tagger; M Favret; M L Ribero; F Callea; C Martelli; A Savio; P Trevisi; G Nardi
Journal:  Cancer Causes Control       Date:  2001-12       Impact factor: 2.506

Review 2.  Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis.

Authors:  A M Diehl
Journal:  Alcohol Clin Exp Res       Date:  2001-05       Impact factor: 3.455

Review 3.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

4.  Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.

Authors:  N Chalasani; A Baluyut; A Ismail; A Zaman; G Sood; R Ghalib; T M McCashland; K R Reddy; X Zervos; M A Anbari; H Hoen
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

5.  Detection of hepatitis C virus RNA sequences in hepatic portal cholangiocarcinoma tissue by reverse transcription polymerase chain reaction.

Authors:  F Yin; B Chen
Journal:  Chin Med J (Engl)       Date:  1998-12       Impact factor: 2.628

6.  Risk factors for cholangiocarcinoma in a low risk Caucasian population.

Authors:  H Kuper; P Lagiou; L A Mucci; R Tamimi; V Benetou; D Trichopoulos
Journal:  Soz Praventivmed       Date:  2001

Review 7.  Cholangiocarcinoma.

Authors:  S A Ahrendt; A Nakeeb; H A Pitt
Journal:  Clin Liver Dis       Date:  2001-02       Impact factor: 6.126

8.  Detection of Helicobacter pylori DNA in human biliary tree and its association with hepatolithiasis.

Authors:  S J Myung; M H Kim; K N Shim; Y S Kim; E O Kim; H J Kim; E T Park; K S Yoo; B C Lim; D W Seo; S K Lee; Y I Min; J Y Kim
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

9.  High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis.

Authors:  V Paradis; G Perlemuter; F Bonvoust; D Dargere; B Parfait; M Vidaud; M Conti; S Huet; N Ba; C Buffet; P Bedossa
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

10.  Risk factors of fibrosis in alcohol-induced liver disease.

Authors:  Bruno Raynard; Axel Balian; David Fallik; Frédérique Capron; Pierre Bedossa; Jean-Claude Chaput; Sylvie Naveau
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

View more
  180 in total

1.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

2.  Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages.

Authors:  Guido Carpino; Vincenzo Cardinale; Paolo Onori; Antonio Franchitto; Pasquale Bartolomeo Berloco; Massimo Rossi; Yunfang Wang; Rossella Semeraro; Maurizio Anceschi; Roberto Brunelli; Domenico Alvaro; Lola M Reid; Eugenio Gaudio
Journal:  J Anat       Date:  2011-12-05       Impact factor: 2.610

Review 3.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.

Authors:  William C Palmer; Tushar Patel
Journal:  J Hepatol       Date:  2012-03-13       Impact factor: 25.083

4.  Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.

Authors:  Ioannis T Konstantinidis; Bas Groot Koerkamp; Richard K G Do; Mithat Gönen; Yuman Fong; Peter J Allen; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; David S Klimstra; Nancy E Kemeny; William R Jarnagin
Journal:  Cancer       Date:  2015-12-22       Impact factor: 6.860

5.  Accomplishments in 2007 in the management of hepatobiliary cancers.

Authors:  Anthony T C Chan; Yoji Kishi; Stephen L Chan; Jean-Nicolas Vauthey
Journal:  Gastrointest Cancer Res       Date:  2008-05

Review 6.  Obesity and cholangiocarcinoma.

Authors:  Mansour A Parsi
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

7.  Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.

Authors:  Alison L Van Dyke; Meredith S Shiels; Gieira S Jones; Ruth M Pfeiffer; Jessica L Petrick; Jennifer L Beebe-Dimmer; Jill Koshiol
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

Review 8.  Early detection of intrahepatic cholangiocarcinoma.

Authors:  Mami Hamaoka; Kazuto Kozaka; Osamu Matsui; Takahiro Komori; Takashi Matsubara; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Wataru Koda; Toshifumi Gabata; Satoshi Kobayashi
Journal:  Jpn J Radiol       Date:  2019-08-01       Impact factor: 2.374

Review 9.  Staging of extrahepatic cholangiocarcinoma.

Authors:  Yong Eun Chung; Myeong-Jin Kim; Young Nyun Park; Yoon-Hee Lee; Jin-Young Choi
Journal:  Eur Radiol       Date:  2008-05-06       Impact factor: 5.315

10.  Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS").

Authors:  Eric A Engels; Ruth Parsons; Caroline Besson; Lindsay M Morton; Lindsey Enewold; Winnie Ricker; Elizabeth L Yanik; Hannah Arem; April A Austin; Ruth M Pfeiffer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-26       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.